177 related articles for article (PubMed ID: 35562598)
1. Alternative- and focal therapy trends for prostate cancer: a total population analysis of in-patient treatments in Germany from 2006 to 2019.
Flegar L; Zacharis A; Aksoy C; Heers H; Derigs M; Eisenmenger N; Borkowetz A; Groeben C; Huber J
World J Urol; 2022 Jul; 40(7):1645-1652. PubMed ID: 35562598
[TBL] [Abstract][Full Text] [Related]
2. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
[TBL] [Abstract][Full Text] [Related]
3. Morbidity of focal therapy in the treatment of localized prostate cancer.
Barret E; Ahallal Y; Sanchez-Salas R; Galiano M; Cosset JM; Validire P; Macek P; Durand M; Prapotnich D; Rozet F; Cathelineau X
Eur Urol; 2013 Apr; 63(4):618-22. PubMed ID: 23265382
[TBL] [Abstract][Full Text] [Related]
4. Contrast enhanced ultrasound (CEUS) with MRI image fusion for monitoring focal therapy of prostate cancer with high intensity focused ultrasound (HIFU)1.
Apfelbeck M; Clevert DA; Ricke J; Stief C; Schlenker B
Clin Hemorheol Microcirc; 2018; 69(1-2):93-100. PubMed ID: 29660918
[TBL] [Abstract][Full Text] [Related]
5. Which technology to select for primary focal treatment of prostate cancer?-European Section of Urotechnology (ESUT) position statement.
Ganzer R; Arthanareeswaran VKA; Ahmed HU; Cestari A; Rischmann P; Salomon G; Teber D; Liatsikos E; Stolzenburg JU; Barret E
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):175-186. PubMed ID: 29743538
[TBL] [Abstract][Full Text] [Related]
6. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).
Noweski A; Roosen A; Lebdai S; Barret E; Emberton M; Benzaghou F; Apfelbeck M; Gaillac B; Gratzke C; Stief C; Azzouzi AR
Eur Urol Focus; 2019 Nov; 5(6):1022-1028. PubMed ID: 29661587
[TBL] [Abstract][Full Text] [Related]
7. Association between Lesion Location and Oncologic Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy.
Stabile A; Sanchez-Salas R; Tourinho-Barbosa R; Macek P; Pellegrino F; Gandaglia G; Moschini M; Cathala N; Mombet A; Montorsi F; Briganti A; Cathelineau X
J Urol; 2021 Sep; 206(3):638-645. PubMed ID: 33890485
[TBL] [Abstract][Full Text] [Related]
8. Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy.
Flegar L; Buerk B; Proschmann R; Propping S; Groeben C; Baunacke M; Herout R; Huber J; Thomas C; Borkowetz A
Eur Urol Focus; 2022 Jan; 8(1):121-127. PubMed ID: 33602642
[TBL] [Abstract][Full Text] [Related]
9. First experiences using transurethral ultrasound ablation (TULSA) as a promising focal approach to treat localized prostate cancer: a monocentric study.
Peters I; Hensen B; Glandorf J; Gutberlet M; Dohna M; Struckmann S; Kuczyk MA; Wacker F; Hellms S
BMC Urol; 2023 Aug; 23(1):142. PubMed ID: 37644453
[TBL] [Abstract][Full Text] [Related]
10. New treatments for localized prostate cancer.
Marberger M; Carroll PR; Zelefsky MJ; Coleman JA; Hricak H; Scardino PT; Abenhaim LL
Urology; 2008 Dec; 72(6 Suppl):S36-43. PubMed ID: 19095127
[TBL] [Abstract][Full Text] [Related]
11. HIFU focal therapy for prostate cancer using intraoperatory contrast enhanced ultrasound.
Claros OR; Tourinho-Barbosa RR; Carneiro A; Collura-Merlier S; Macek P; Lanz C; Cathala N; Prapotnich D; Mombet A; Sanchez-Salas R; Cathelineau X
Arch Esp Urol; 2019 Oct; 72(8):825-830. PubMed ID: 31579041
[TBL] [Abstract][Full Text] [Related]
12. Focal Therapy for Renal Cancer: Comparative Trends in the USA and Germany from 2006 to 2020 and Analysis of the German Health Care Landscape.
Flegar L; Thoduka SG; Mahnken AH; Figiel J; Heers H; Aksoy C; Eisenmenger N; Groeben C; Huber J; Zacharis A
Urol Int; 2023; 107(4):396-405. PubMed ID: 36702105
[TBL] [Abstract][Full Text] [Related]
13. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
Chin JL; Billia M; Relle J; Roethke MC; Popeneciu IV; Kuru TH; Hatiboglu G; Mueller-Wolf MB; Motsch J; Romagnoli C; Kassam Z; Harle CC; Hafron J; Nandalur KR; Chronik BA; Burtnyk M; Schlemmer HP; Pahernik S
Eur Urol; 2016 Sep; 70(3):447-55. PubMed ID: 26777228
[TBL] [Abstract][Full Text] [Related]
14. Oncological Outcome and Value of Postoperative Magnetic Resonance Imaging after Focal High-Intensity Focused Ultrasound Therapy for Prostate Cancer.
Rosenhammer B; Niessen C; Rotzinger L; Reiss J; Schnabel MJ; Burger M; Bründl J
Urol Int; 2019; 103(3):270-278. PubMed ID: 31466073
[TBL] [Abstract][Full Text] [Related]
15. High-Intensity Focused Ultrasound for the Treatment of Prostate Cancer: A Review.
Chaussy CG; Thüroff S
J Endourol; 2017 Apr; 31(S1):S30-S37. PubMed ID: 28355119
[TBL] [Abstract][Full Text] [Related]
16. Ablation energies for focal treatment of prostate cancer.
Lodeizen O; de Bruin M; Eggener S; Crouzet S; Ghai S; Varkarakis I; Katz A; Dominguez-Escrig JL; Pahernik S; de Reijke T; de la Rosette J
World J Urol; 2019 Mar; 37(3):409-418. PubMed ID: 29943219
[TBL] [Abstract][Full Text] [Related]
17. Cryoablation, high-intensity focused ultrasound, irreversible electroporation, and vascular-targeted photodynamic therapy for prostate cancer: a systemic review and meta-analysis.
Guo RQ; Guo XX; Li YM; Bie ZX; Li B; Li XG
Int J Clin Oncol; 2021 Mar; 26(3):461-484. PubMed ID: 33387088
[TBL] [Abstract][Full Text] [Related]
18. Follow-up after focal therapy of the prostate with high intensity focused ultrasound (HIFU) using contrast enhanced ultrasound (CEUS) in combination with MRI image fusion.
Apfelbeck M; Chaloupka M; Schlenker B; Stief CG; Clevert DA
Clin Hemorheol Microcirc; 2019; 73(1):135-143. PubMed ID: 31561350
[TBL] [Abstract][Full Text] [Related]
19. TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.
Azzouzi AR; Barret E; Bennet J; Moore C; Taneja S; Muir G; Villers A; Coleman J; Allen C; Scherz A; Emberton M
World J Urol; 2015 Jul; 33(7):945-53. PubMed ID: 25712310
[TBL] [Abstract][Full Text] [Related]
20. [High-intensity focussed ultrasound in low-risk prostate cancer - oncological outcome and postinterventional quality of life of an inexperienced therapy centre in comparison with an experienced therapy centre].
Baumunk D; Andersen C; Heile U; Ebbing J; Cash H; Porsch M; Liehr UB; Janitzky A; Wendler JJ; Schindele D; Blaschke S; Miller K; Schostak M
Aktuelle Urol; 2013 Jul; 44(4):285-92. PubMed ID: 23888408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
